➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Boehringer Ingelheim
Harvard Business School
Express Scripts
Johnson and Johnson

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CAMPATH

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for CAMPATH

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001984 ↗ Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 1999-11-01 This protocol will test a humanized monoclonal antibody known as Campath-1H for its ability to induce a state of permanent allograft acceptance, or tolerance, when administered in combination with a brief course of the immunosuppressive drug deoxyspergualin (DSG) at the time of human renal allotransplantation. Campath-1H is specific for the common lymphocyte and monocyte antigen CD52. Its administration temporarily depletes mature lymphocytes and some monocytes without altering neutrophils or hematopoietic stem cells. Deoxyspergualin inhibits the NFkB pathway thus preventing monocyte and macrophage activation. Recipients of living or cadaveric donor kidneys will be treated with one dose of Campath-1H prior to transplantation to insure that peripheral depletion is achieved at the time of graft reperfusion. Three subsequent doses of Campath-1H will be administered on the first, third and fifth days after the transplant to deplete passenger donor leukocytes and residual recipient cells that mobilize in response to the allograft. In addition, patients will be treated with DSG for 14 days beginning on the day prior to surgery. This trial expands on pilot studies at the NIH of 15 patients in which Campath was given alone at the time of transplantation. In those studies, excellent peripheral depletion occurred after just one dose of Campath though central depletion required additional dosing. This allowed for greatly reduced immunosuppression to be used to prevent rejection, but to date, all patients have required some immunosuppressive medication. It is hoped that the addition of DSG will eliminate the need for long-term immunosuppression. Patients will be followed closely in the post transplant period. If patients experience rejection, they will be treated with methylprednisolone and have immunosuppression added using sirolimus as the predominant immunosuppressive agent. In the previous phase of this study without DSG, this maneuver has in all cases been successful in returning the allograft to normal function. In addition to evaluating graft function following transplantation, this protocol will also characterize and evaluate the function of the immune system and the composition of the T cell repertoire following the administration of Campath-1H and DSG, and during immune system recovery after transplantation.
NCT00004143 ↗ Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed David Rizzieri, MD Phase 2 1999-09-01 RATIONALE: Although used primarily to treat malignant disorders of the blood, allogeneic stem cell transplantation can also cure a variety of non-cancerous, inherited or acquired disorders of the blood. Unfortunately, the conventional approach to allogeneic stem cell transplantation is a risky procedure. For some non-cancerous conditions, the risks of this procedure outweigh the potential benefits. This protocol is designed to test a new approach to allogeneic stem cell transplantation. It is hoped that this approach will be better suited for patients with non-cancerous blood and bone marrow disorders.
NCT00004857 ↗ Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia Completed National Cancer Institute (NCI) Phase 2 2000-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as alemtuzumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine followed by alemtuzumab in treating patients who have chronic lymphocytic leukemia.
NCT00004857 ↗ Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia Completed Alliance for Clinical Trials in Oncology Phase 2 2000-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as alemtuzumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine followed by alemtuzumab in treating patients who have chronic lymphocytic leukemia.
NCT00006390 ↗ Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia Completed National Cancer Institute (NCI) Phase 2 2001-02-01 RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. Combining monoclonal antibody therapy, chemotherapy, radiation therapy, and peripheral stem cell transplantation may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of alemtuzumab plus peripheral stem cell transplantation in treating patients who have chronic lymphocytic leukemia.
NCT00006390 ↗ Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia Completed Eastern Cooperative Oncology Group Phase 2 2001-02-01 RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. Combining monoclonal antibody therapy, chemotherapy, radiation therapy, and peripheral stem cell transplantation may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of alemtuzumab plus peripheral stem cell transplantation in treating patients who have chronic lymphocytic leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CAMPATH

Condition Name

Condition Name for CAMPATH
Intervention Trials
Leukemia 30
Lymphoma 18
Chronic Lymphocytic Leukemia 12
Sickle Cell Disease 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CAMPATH
Intervention Trials
Leukemia 48
Leukemia, Lymphoid 36
Lymphoma 33
Leukemia, Lymphocytic, Chronic, B-Cell 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CAMPATH

Trials by Country

Trials by Country for CAMPATH
Location Trials
United States 310
United Kingdom 8
Canada 7
Italy 4
Austria 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CAMPATH
Location Trials
Texas 45
Maryland 20
New York 18
Ohio 17
Minnesota 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CAMPATH

Clinical Trial Phase

Clinical Trial Phase for CAMPATH
Clinical Trial Phase Trials
Phase 4 14
Phase 3 8
Phase 2/Phase 3 3
[disabled in preview] 140
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CAMPATH
Clinical Trial Phase Trials
Completed 71
Terminated 42
Recruiting 29
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CAMPATH

Sponsor Name

Sponsor Name for CAMPATH
Sponsor Trials
National Cancer Institute (NCI) 21
Baylor College of Medicine 20
Bayer 19
[disabled in preview] 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CAMPATH
Sponsor Trials
Other 253
Industry 54
NIH 40
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Baxter
Boehringer Ingelheim
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.